Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt 2.30
AGN's Cash to Debt is ranked higher than
69% of the 1153 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.14 vs. AGN: 2.30 )
AGN' s 10-Year Cash to Debt Range
Min: 0.32   Max: 2.3
Current: 2.3

0.32
2.3
Equity to Asset 0.62
AGN's Equity to Asset is ranked higher than
71% of the 957 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.59 vs. AGN: 0.62 )
AGN' s 10-Year Equity to Asset Range
Min: 0.41   Max: 0.64
Current: 0.62

0.41
0.64
Interest Coverage 28.95
AGN's Interest Coverage is ranked higher than
60% of the 618 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 236.52 vs. AGN: 28.95 )
AGN' s 10-Year Interest Coverage Range
Min: 3.29   Max: 46.04
Current: 28.95

3.29
46.04
F-Score: 7
Z-Score: 11.59
M-Score: -2.62
WACC vs ROIC
1.98%
30.47%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating margin (%) 27.76
AGN's Operating margin (%) is ranked higher than
95% of the 1102 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.08 vs. AGN: 27.76 )
AGN' s 10-Year Operating margin (%) Range
Min: -1.34   Max: 28.72
Current: 27.76

-1.34
28.72
Net-margin (%) 21.06
AGN's Net-margin (%) is ranked higher than
94% of the 1102 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.34 vs. AGN: 21.06 )
AGN' s 10-Year Net-margin (%) Range
Min: -6.96   Max: 21.06
Current: 21.06

-6.96
21.06
ROE (%) 21.94
AGN's ROE (%) is ranked higher than
91% of the 1128 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.08 vs. AGN: 21.94 )
AGN' s 10-Year ROE (%) Range
Min: -11.73   Max: 41.11
Current: 21.94

-11.73
41.11
ROA (%) 13.53
AGN's ROA (%) is ranked higher than
92% of the 1163 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.54 vs. AGN: 13.53 )
AGN' s 10-Year ROA (%) Range
Min: -6.6   Max: 18.8
Current: 13.53

-6.6
18.8
ROC (Joel Greenblatt) (%) 134.67
AGN's ROC (Joel Greenblatt) (%) is ranked higher than
98% of the 1158 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.77 vs. AGN: 134.67 )
AGN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -5   Max: 141.95
Current: 134.67

-5
141.95
Revenue Growth (3Y)(%) 10.90
AGN's Revenue Growth (3Y)(%) is ranked higher than
79% of the 936 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.80 vs. AGN: 10.90 )
AGN' s 10-Year Revenue Growth (3Y)(%) Range
Min: -3.1   Max: 19.6
Current: 10.9

-3.1
19.6
EBITDA Growth (3Y)(%) 13.10
AGN's EBITDA Growth (3Y)(%) is ranked higher than
81% of the 833 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.60 vs. AGN: 13.10 )
AGN' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -46   Max: 96
Current: 13.1

-46
96
EPS Growth (3Y)(%) 18.70
AGN's EPS Growth (3Y)(%) is ranked higher than
85% of the 813 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.40 vs. AGN: 18.70 )
AGN' s 10-Year EPS Growth (3Y)(%) Range
Min: 0   Max: 82.1
Current: 18.7

0
82.1
» AGN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

AGN Guru Trades in Q2 2014

Richard Perry 1,667,625 sh (New)
Paul Singer 281,700 sh (New)
Andreas Halvorsen 803,369 sh (New)
Eric Mindich 901,000 sh (New)
John Paulson 5,602,000 sh (New)
Jean-Marie Eveillard 30,000 sh (New)
Jim Chanos 45,300 sh (New)
Louis Moore Bacon 60,000 sh (New)
Bill Ackman 28,878,538 sh (+4733.79%)
Jim Simons 416,395 sh (+153.20%)
Mario Gabelli 131,198 sh (+3.37%)
Steven Cohen 371,500 sh (unchged)
Dodge & Cox 3,564 sh (unchged)
Bill Ackman 28,878,638 sh (unchged)
Ray Dalio Sold Out
Pioneer Investments 804,629 sh (-6.83%)
Ken Fisher 6,183 sh (-7.51%)
Jeremy Grantham 973,051 sh (-11.68%)
Joel Greenblatt 16,281 sh (-13.60%)
Paul Tudor Jones 2,900 sh (-70.96%)
» More
Q3 2014

AGN Guru Trades in Q3 2014

Andreas Halvorsen 2,279,736 sh (+183.77%)
Eric Mindich 1,683,251 sh (+86.82%)
Pioneer Investments 838,740 sh (unchged)
Bill Ackman 28,878,538 sh (unchged)
Bill Ackman 28,878,638 sh (unchged)
Richard Perry Sold Out
Paul Singer Sold Out
Ken Fisher 6,015 sh (-2.72%)
John Paulson 5,377,200 sh (-4.01%)
Mario Gabelli 123,938 sh (-5.53%)
Jeremy Grantham 900,754 sh (-7.43%)
Dodge & Cox 3,264 sh (-8.42%)
Paul Tudor Jones 2,300 sh (-20.69%)
Steven Cohen 274,900 sh (-26.00%)
Louis Moore Bacon 31,870 sh (-46.88%)
Jim Simons 193,595 sh (-53.51%)
Joel Greenblatt 5,670 sh (-65.17%)
Jim Chanos 15,330 sh (-66.16%)
Jean-Marie Eveillard 10,000 sh (-66.67%)
» More
Q4 2014

AGN Guru Trades in Q4 2014

Daniel Loeb 400,000 sh (New)
Larry Robbins 629,647 sh (New)
George Soros 494,786 sh (New)
Paul Singer 992,887 sh (New)
Jean-Marie Eveillard 634,476 sh (+6244.76%)
Paul Tudor Jones 6,797 sh (+195.52%)
Jeremy Grantham 1,464,872 sh (+62.63%)
Jim Simons 297,860 sh (+53.86%)
John Paulson 6,370,000 sh (+18.46%)
Pioneer Investments 887,293 sh (+5.79%)
Eric Mindich 1,705,933 sh (+1.35%)
Dodge & Cox 3,264 sh (unchged)
Bill Ackman 26,635,978 sh (unchged)
Bill Ackman 26,635,978 sh (unchged)
Jim Chanos Sold Out
Ken Fisher 5,972 sh (-0.71%)
Bill Ackman 26,635,978 sh (-7.77%)
Andreas Halvorsen 1,966,112 sh (-13.76%)
Mario Gabelli 69,780 sh (-43.70%)
Louis Moore Bacon 16,374 sh (-48.62%)
Joel Greenblatt 945 sh (-83.33%)
Steven Cohen 21,900 sh (-92.03%)
» More
2015

AGN Guru Trades in 2015

Bill Ackman Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with AGN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Allergan Inc

Ruane, Cunniff & Goldfarb Inc Comments on Valeant
A topic many shareholders and clients wanted to discuss with us in 2014 was Valeant (VRX). It is the largest holding in Sequoia by far. One could argue Valeant wasted much of the year on a quixotic effort to buy Allergan (AGN), maker of Botox. Allergan had no interest in being acquired and fought a vicious and savvy public relations campaign to portray Valeant as unworthy of marriage to such a prized catch. In the end, Allergan found a suitor more to its liking in Actavis (ACT), and Actavis agreed to pay a substantially higher price than Valeant had offered. Read more...
Ackman's Pershing Square Now Available To The Public
Bill Ackman’s Pershing Square Holdings started trading on the Euronext Amsterdam under the symbol “PSH” on October 13. Daniel Loeb had a similar IPO in 2007 on the London Stock Exchange with his fund, Third Point Offshore (LSE:TPOU, LSE:TPOG, TPNTF). The goal of the IPO is to raise permanent capital to help the activist investor maintain his positions in target companies during times of turbulence. If too many investors have redemption requests in the hedge fund, the manager will not be able to maintain a position of control over all of the companies in the portfolio. Read more...
Bill Ackman's Midas Touch
Outside the investment community, the name of Bill Ackman (Trades, Portfolio) of Pershing Square might not raise as many eyebrows as the name of a guru like Warren Buffett (Trades, Portfolio), but Ackman’s track record is still impressive. He seems to have the Midas touch, even more of one than many of the gurus followed by GuruFocus. Read more...
Bill Ackman and Valeant Pharmaceuticals Team Up to Take Over Pharmaceutical Company Allergen
Over the past week GuruFocus Real Time Picks reported that Bill Ackman (Trades, Portfolio) made a buy into Allergen (AGN). This is the first buy into the company for Ackman, and he did so in a big way by purchasing a total of 28,878,538 shares of the company’s stock. He bought these shares at the average price of $120.89 per share on April 11, and since this buy the price per share is up 35% to $163.65. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 47.90
AGN's P/E(ttm) is ranked higher than
73% of the 1277 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 59.80 vs. AGN: 47.90 )
AGN' s 10-Year P/E(ttm) Range
Min: 16.7   Max: 79.22
Current: 47.9

16.7
79.22
Forward P/E 23.04
AGN's Forward P/E is ranked higher than
81% of the 1277 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. AGN: 23.04 )
N/A
PE(NRI) 47.90
AGN's PE(NRI) is ranked higher than
77% of the 1277 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 56.20 vs. AGN: 47.90 )
AGN' s 10-Year PE(NRI) Range
Min: 16.7   Max: 77.47
Current: 47.9

16.7
77.47
P/B 9.23
AGN's P/B is ranked lower than
53% of the 1277 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.10 vs. AGN: 9.23 )
AGN' s 10-Year P/B Range
Min: 2.4   Max: 12.73
Current: 9.23

2.4
12.73
P/S 10.05
AGN's P/S is ranked lower than
64% of the 1277 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.25 vs. AGN: 10.05 )
AGN' s 10-Year P/S Range
Min: 2.18   Max: 10.05
Current: 10.05

2.18
10.05
PFCF 44.24
AGN's PFCF is ranked higher than
82% of the 1277 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. AGN: 44.24 )
AGN' s 10-Year PFCF Range
Min: 16.97   Max: 143.81
Current: 44.24

16.97
143.81
POCF 37.83
AGN's POCF is ranked higher than
77% of the 1277 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 45.64 vs. AGN: 37.83 )
AGN' s 10-Year POCF Range
Min: 13.85   Max: 77.53
Current: 37.83

13.85
77.53
EV-to-EBIT 34.50
AGN's EV-to-EBIT is ranked higher than
76% of the 1277 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 40.16 vs. AGN: 34.50 )
AGN' s 10-Year EV-to-EBIT Range
Min: -6103.8   Max: 773.4
Current: 34.5

-6103.8
773.4
PEG 1.92
AGN's PEG is ranked higher than
93% of the 1277 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. AGN: 1.92 )
AGN' s 10-Year PEG Range
Min: 0.41   Max: 12.32
Current: 1.92

0.41
12.32
Shiller P/E 83.57
AGN's Shiller P/E is ranked higher than
74% of the 1277 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. AGN: 83.57 )
AGN' s 10-Year Shiller P/E Range
Min: 32.89   Max: 110.83
Current: 83.57

32.89
110.83
Current Ratio 4.41
AGN's Current Ratio is ranked higher than
85% of the 1023 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.20 vs. AGN: 4.41 )
AGN' s 10-Year Current Ratio Range
Min: 1.58   Max: 4.5
Current: 4.41

1.58
4.5
Quick Ratio 4.22
AGN's Quick Ratio is ranked higher than
87% of the 1023 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.70 vs. AGN: 4.22 )
AGN' s 10-Year Quick Ratio Range
Min: 1.21   Max: 4.26
Current: 4.22

1.21
4.26
Days Inventory 127.86
AGN's Days Inventory is ranked higher than
72% of the 1277 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 139.62 vs. AGN: 127.86 )
AGN' s 10-Year Days Inventory Range
Min: 79.46   Max: 179.87
Current: 127.86

79.46
179.87
Days Sales Outstanding 46.12
AGN's Days Sales Outstanding is ranked higher than
88% of the 1277 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 89.57 vs. AGN: 46.12 )
AGN' s 10-Year Days Sales Outstanding Range
Min: 38.34   Max: 100.37
Current: 46.12

38.34
100.37

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.10
AGN's Dividend Yield is ranked lower than
90% of the 687 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.30 vs. AGN: 0.10 )
AGN' s 10-Year Dividend Yield Range
Min: 0.08   Max: 0.63
Current: 0.1

0.08
0.63
Dividend Payout 0.04
AGN's Dividend Payout is ranked higher than
100% of the 1277 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. AGN: 0.04 )
AGN' s 10-Year Dividend Payout Range
Min: 0.04   Max: 0.63
Current: 0.04

0.04
0.63
Yield on cost (5-Year) 0.10
AGN's Yield on cost (5-Year) is ranked lower than
90% of the 694 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.54 vs. AGN: 0.10 )
AGN' s 10-Year Yield on cost (5-Year) Range
Min: 0.08   Max: 0.63
Current: 0.1

0.08
0.63
Share Buyback Rate 0.70
AGN's Share Buyback Rate is ranked higher than
90% of the 778 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -1.10 vs. AGN: 0.70 )
AGN' s 10-Year Share Buyback Rate Range
Min: 1.1   Max: -4.8
Current: 0.7

Valuation & Return

vs
industry
vs
history
Price/Net Cash 237.80
AGN's Price/Net Cash is ranked higher than
79% of the 1277 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. AGN: 237.80 )
AGN' s 10-Year Price/Net Cash Range
Min: 210.49   Max: 1079.6
Current: 237.8

210.49
1079.6
Price/Net Current Asset Value 63.20
AGN's Price/Net Current Asset Value is ranked higher than
74% of the 1277 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. AGN: 63.20 )
AGN' s 10-Year Price/Net Current Asset Value Range
Min: 17.31   Max: 198.92
Current: 63.2

17.31
198.92
Price/Tangible Book 20.00
AGN's Price/Tangible Book is ranked lower than
55% of the 1277 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.50 vs. AGN: 20.00 )
AGN' s 10-Year Price/Tangible Book Range
Min: 3.31   Max: 118.96
Current: 20

3.31
118.96
Price/DCF (Projected) 3.80
AGN's Price/DCF (Projected) is ranked higher than
83% of the 1277 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. AGN: 3.80 )
AGN' s 10-Year Price/DCF (Projected) Range
Min: 1.3   Max: 6.46
Current: 3.8

1.3
6.46
Price/Median PS Value 2.00
AGN's Price/Median PS Value is ranked higher than
58% of the 1277 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.50 vs. AGN: 2.00 )
AGN' s 10-Year Price/Median PS Value Range
Min: 0.36   Max: 2.31
Current: 2

0.36
2.31
Price/Peter Lynch Fair Value 1.90
AGN's Price/Peter Lynch Fair Value is ranked higher than
94% of the 1277 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. AGN: 1.90 )
AGN' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.89   Max: 4.79
Current: 1.9

0.89
4.79
Price/Graham Number 6.50
AGN's Price/Graham Number is ranked higher than
69% of the 1277 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. AGN: 6.50 )
AGN' s 10-Year Price/Graham Number Range
Min: 1.55   Max: 48.02
Current: 6.5

1.55
48.02
Earnings Yield (Greenblatt) 2.90
AGN's Earnings Yield (Greenblatt) is ranked higher than
70% of the 1150 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. AGN: 2.90 )
AGN' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 8.1
Current: 2.9

0.1
8.1
Forward Rate of Return (Yacktman) 33.70
AGN's Forward Rate of Return (Yacktman) is ranked higher than
94% of the 582 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.44 vs. AGN: 33.70 )
AGN' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -24.5   Max: 51.2
Current: 33.7

-24.5
51.2

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, FRX, MRX, ESALF » details
Traded in other countries:AG4.Germany,
Allergan Inc incorporated in Delaware in 1977. It is a multi-specialty health care company. The Company is engaged in the developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter products that enable people to live life to its full potential - to see more clearly, move more freely and express themselves more fully. It offers products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets in more than 100 countries around the world. It is also engaged in specialty pharmaceutical, biologic and medical device research and development. The Company's business segments are specialty pharmaceuticals and medical devices. The specialty pharmaceuticals segment produces pharmaceutical products, including: ophthalmic products for dry eye, glaucoma, inflammation, infection, allergy and retinal disease; Botox for certain therapeutic and aesthetic indications; skin care products for acne, psoriasis, eyelash growth and other prescription and over-the-counter skin care products; and urologics products. The medical devices segment produces medical devices, including: breast implants for augmentation, revision and reconstructive surgery and tissue expanders; and facial aesthetics products. The Company sells its products directly through its own sales subsidiaries in approximately 40 countries and, supplemented by independent distributors, in over 100 countries. Its products are sold to drug wholesalers, independent and chain drug stores, pharmacies, commercial optical chains, opticians, mass merchandisers, food stores, hospitals, group purchasing organizations, integrated direct hospital networks, ambulatory surgery centers, government purchasing agencies and medical practitioners. The Company also utilize distributors for its products in smaller international markets. The Company's competitors include Akorn, Inc., Alcon Laboratories, Inc./Novartis AG, Abbott Laboratories, Alimera Sciences, Inc., Bausch & Lomb, Inc., a division of Valeant, Genentech/Hoffmann La Roche AG, Merck & Co., Pfizer Inc., Regeneron Pharmaceuticals, Inc. and Santen Seiyaku. Mentor and Sientra, Inc., or Sientra, a partner of Silimed, LifeCell Corporation, CR Bard Inc. The Company's operations are subject to federal, state, local and foreign environmental laws and regulations, including the U.S. Occupational Safety and Health Act, the U.S. Toxic Substances Control Act, the U.S. Resource Conservation and Recovery Act, Superfund Amendments and Reauthorization Act, Comprehensive Environmental Response, Compensation and Liability Act and other current and potential future federal, state or local regulations.
» More Articles for AGN

Headlines

Articles On GuruFocus.com
Valeant Finally Bags Salix for $11 Billion Apr 06 2015 
Pershing Square Holdings: First Annual Report Mar 25 2015 
Ruane, Cunniff & Goldfarb Inc Comments on Valeant Mar 16 2015 
personal Mar 10 2015 
Valeant Pharmaceuticals Finally Zeros In On Salix Pharmaceuticals Feb 24 2015 
Weekly 52-Week Highs Highlight: DG, AGN, ADSK, AVGO, PCYC Feb 22 2015 
John Paulson's Top Buys Feb 22 2015 
A Look at Larry Robbins and His Latest Portfolio Update Feb 20 2015 
Aegean Metals Group Inc. Announces Closing of Arrangement Jan 16 2015 
Aegean Commences Drilling at Hot Maden Gold-Copper Project, Eastern Turkey Dec 15 2014 

More From Other Websites
Valeant closes $11B deal for Raleigh's Salix Pharmaceuticals Apr 01 2015
Salix had a $13B offer on the table before accounting problems crashed share price Mar 24 2015
Talking Allergan at Tulane: a 'Horse Choker,' the 'Shamarendum' and More Mar 24 2015
ALLERGAN INC Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Notice of... Mar 18 2015
Sale of Allergan to Actavis is finalized; CEO David Pyott stepping down Mar 17 2015
Actavis' Depression Drug Gains FDA Approval for New Dose - Analyst Blog Mar 17 2015
Cramer: Market cross currents Mar 17 2015
Valeant (VRX) Raises Salix Offer, Endo Withdraws Proposal - Analyst Blog Mar 17 2015
Allergan sale complete, CEO Pyott steps down Mar 17 2015
American Airlines Group (AAL) to Enter Coveted S&P 500 - Analyst Blog Mar 17 2015
Allergan sale to Actavis complete; CEO David Pyott is leaving Mar 17 2015
Pharma Stock Outlook: Let's Make a Deal - Industry Outlook Mar 17 2015
Pharma Stock Outlook: Let's Make a Deal - Zacks Analyst Interviews Mar 17 2015
Actavis Completes Acquisition of Allergan Mar 17 2015
American Airlines Joining The S&P 500, Analysts Bullish On U.S. Skies Mar 17 2015
Cramer's Stop Trading: ESPR Mar 17 2015
Actavis says Allergan's Pyott won't join new company's board Mar 17 2015
American Airlines Replaces Allergan in S&P 500 Mar 17 2015
Actavis Completes Allergan Acquisition Mar 17 2015
Cramer's Mad Dash: ACT & MGM Mar 17 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK